Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
| Tracking Information | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | April 30, 2012 | ||||||||||||||||||||
| Last Updated Date | May 1, 2012 | ||||||||||||||||||||
| Start Date ICMJE | July 2012 | ||||||||||||||||||||
| Estimated Primary Completion Date | July 2014 (final data collection date for primary outcome measure) | ||||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
Length of stay as measured by the time from initial diagnosis of ACS until meeting discharge criteria. [ Time Frame: From diagnosis of ACS until meeting discharge criteria- Average 7 days. ] [ Designated as safety issue: No ] | ||||||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||
| Change History | Complete list of historical versions of study NCT01589926 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||
| Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||
| Descriptive Information | |||||||||||||||||||||
| Brief Title ICMJE | Bi-Level Positive Airway Ventilation for Acute Chest Syndrome | ||||||||||||||||||||
| Official Title ICMJE | Early Bi-Level Positive Airway Pressure (BLPAP) Ventilation for Acute Chest Syndrome (ACS) - a Double-Blind Randomized Controlled Pilot Study | ||||||||||||||||||||
| Brief Summary | Acute chest syndrome (ACS) is a frequent complication of sickle cell disease and is diagnosed by having findings on a chest x-ray and one of the following: chest pain, fever, or trouble breathing. Patients with Acute Chest Syndrome can get very sick and require an exchange transfusion (special large blood transfusion) and mechanical ventilation. Bi-level Positive Airway Pressure (BLPAP) is a device that blows air into a patients lungs via a mask that covers the nose. Our goal is to determine whether giving children BLPAP when they have ACS, in addition to providing standard clinical care for ACS alters the clinical course of these patients. The investigators hypothesize that patients receiving effective BLPAP will have milder clinical courses resulting in shorter hospital stays and fewer transfers to the intensive care unit and exchange transfusions. |
||||||||||||||||||||
| Detailed Description | Acute chest syndrome (ACS) is a frequent complication of sickle cell disease and is diagnosed by a new infiltrate on chest x-ray and one of the following: chest pain, fever, or respiratory signs or symptoms (tachypnea, cough, new onset hypoxemia, or increased work of breathing.)The treatment for acute chest syndrome is focused on supportive care with hydration, antibiotics, blood transfusions and respiratory support. Unfortunately, despite these treatments many patients fail to have improvements in their respiratory status, or have respiratory decompensation. These patients require more aggressive treatments, which frequently include exchange transfusions, pediatric intensive care unit (PCCU) management, and respiratory support. Our goal is to perform a prospective double blind randomized control trial to investigate if early initiation of effective BLPAP in addition to providing standard clinical care for ACS alters the clinical course of these patients vs. sham BLPAP and standard clinical care. We hypothesize that patients receiving effective BLPAP will have milder clinical courses resulting in shorter hospital stays and fewer transfers to PCCU and exchange transfusions. |
||||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||||
| Study Phase | Not Provided | ||||||||||||||||||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Supportive Care |
||||||||||||||||||||
| Condition ICMJE |
|
||||||||||||||||||||
| Intervention ICMJE |
|
||||||||||||||||||||
| Study Arm (s) |
|
||||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||
| Recruitment Status ICMJE | Not yet recruiting | ||||||||||||||||||||
| Estimated Enrollment ICMJE | 60 | ||||||||||||||||||||
| Estimated Completion Date | July 2014 | ||||||||||||||||||||
| Estimated Primary Completion Date | July 2014 (final data collection date for primary outcome measure) | ||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria: Hemoglobin SS, SC, SB0thal or SBthal Ages ≥ 4-21 years old Patients are admitted to the hematology oncology inpatient service and have been enrolled and consented in the study. Meet clinical criteria for ACS- an infiltrate on Chest X-ray and one of the following:
Patients' eligible for a simple transfusion based on one of the following criteria:
Exclusion Criteria:
|
||||||||||||||||||||
| Gender | Both | ||||||||||||||||||||
| Ages | 4 Years to 21 Years | ||||||||||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||||||||||
| Contacts ICMJE |
|
||||||||||||||||||||
| Location Countries ICMJE | United States | ||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||
| NCT Number ICMJE | NCT01589926 | ||||||||||||||||||||
| Other Study ID Numbers ICMJE | NCT01532001 | ||||||||||||||||||||
| Has Data Monitoring Committee | Yes | ||||||||||||||||||||
| Responsible Party | Michael Roth, Albert Einstein College of Medicine of Yeshiva University | ||||||||||||||||||||
| Study Sponsor ICMJE | Albert Einstein College of Medicine of Yeshiva University | ||||||||||||||||||||
| Collaborators ICMJE | Not Provided | ||||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||||
| Information Provided By | Albert Einstein College of Medicine of Yeshiva University | ||||||||||||||||||||
| Verification Date | May 2012 | ||||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||||